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Short summary: This interventional study of 3 consecutive monthly treatments of a standard 46 
3-day course of DHA/PQP raised no cardiac safety concerns, including no evidence of QTcF 47 
lengthening with cumulative dosing, and overall QTcF prolongation similar to that previously 48 




Background: Mass drug administration (MDA) of sequential rounds of antimalarial drugs is 51 
being considered as a tool for malaria elimination. As an effective and long-acting 52 
antimalarial, Dihydroartemisinin-piperaquine (DHA/PQP) appears suitable as a candidate for 53 
MDA. However, absence of cardiac safety data following repeated administration hinders its 54 
use in the extended schedules proposed for MDA.  55 
Methods: We conducted an interventional study in Lihir Island, Papua New Guinea, with 56 
healthy individuals aged 3 to 60 years who received a standard 3-day course of DHA/PQP on 57 
3 consecutive months. Twelve-lead electrocardiography (ECG) readings were conducted pre-58 
dose and 4h after the final dose of each month. The primary safety endpoint was QTc (using 59 
Fridericia’s correction; QTcF) prolongation from baseline to 4h post-dosing. We compared 60 
the difference in prolongation between the third course post-dose and the first course post-61 
dose. 62 
Results: Of 84 enrolled participants, 69 (82%) completed all treatment courses and ECG 63 
measurements. The average increase in QTcF was 19.6 ms (SD 17.8) and 17.1 ms (SD 17.1) 64 
for the first-course and third-course post-dosing ECGs [risk difference -2.4 (95%CI - 6.9 to 65 
2.1), p=0.285], respectively. We recorded QTcF prolongation >60 ms from baseline in 3 66 
(4.3%) and 2 (2.9%) participants after the first course and third course (p=1.00), respectively. 67 
No participants had QTcF intervals >500 ms at any time point.  68 
Conclusions: Three consecutive monthly courses of DHA/PQP were as safe as a single 69 
course. The absence of cumulative cardiotoxicity with repeated dosing support the use of 70 





Malaria elimination is set to be a global health priority in coming years and ambitious plans 74 
for scaling up from malaria control to elimination already exist in much of the malaria-75 
endemic world. New strategies being actively considered for interrupting malaria 76 
transmission include mass drug administration (MDA)(1). This strategy requires the 77 
treatment of entire populations with effective antimalarial drugs to reduce the human 78 
reservoir of symptomatic and asymptomatic blood stage infections, in addition to conferring 79 
post-treatment prophylaxis that prevents re-infection and relapse over a time period that 80 
significantly exceeds the lifespan of the anopheline vector (2). Because most individuals 81 
treated in an MDA program are asymptomatic parasite carriers or uninfected, the ideal 82 
antimalarial for MDA must i) have a prolonged duration of effect that optimises the period of 83 
prophylaxis against reinfection and relapse and ii) be demonstrated to be safe when delivered 84 
in sequential repeated treatment courses in the manner proposed for MDA deployment (2). 85 
Dihydroartemisinin-piperaquine (DHA/PQP) is a good candidate for MDA. The rapid-acting 86 
artemisinin-derivative reduces the parasite biomass of existing infections and the long-acting 87 
PQP component exerts an especially long post-treatment prophylactic effect (3). Repeated 88 
monthly exposure to standard 3-day treatment courses of DHA/PQP over 3 consecutive 89 
months should theoretically prevent new infections for a period of at least 90-120 days. In a 90 
meta-analysis of 11 studies, monthly DHA/PQP for high-risk populations was associated with 91 
an 84% reduction in the incidence of malaria parasitaemia (4-6). 92 
Nevertheless, the feasibility of DHA/PQP for MDA has been questioned because PQP can 93 
cause dose-dependent prolongation of the electrocardiographic QT interval. As such, PQP is 94 
contraindicated in patients with congenital long QT syndrome (about one in 2500 children) or 95 
those taking other drugs that prolong the QT. Mild QT prolongation is clinically silent, but 96 
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extreme prolongation can cause fatal arrhythmias such as Torsades de Pointes (TdP). Prior 97 
studies have demonstrated that QTc prolongation associated with DHA/PQP is predominantly 98 
mild and not associated with clinical adverse cardiac outcomes (4, 7). However, PQP is 99 
eliminated slowly (elimination half-life ~ 23 days) and the risk of QT prolongation may be 100 
exacerbated when repeated doses are given, especially if given monthly (8). Therefore, the 101 
drug manufacturer and the European Medicines Agency (EMA) recommend that repeated 102 
treatment courses of DHA/PQP with the brand name Eurartesim 160mg/20mg film coated 103 
tablets should not be administered within two months of initial treatment (9). Unfortunately, 104 
this is unlikely to be optimally effective if DHA/PQP is given as MDA; mathematical models 105 
suggest a maximum interval of one month between treatment rounds is required to interrupt 106 
transmission (10).  107 
The current study aims to assess the cardiac safety of three repeated monthly courses of 108 
DHA/PQP, in Lihir island, PNG, a malaria-endemic population likely to be targeted in future 109 
MDA activities. 110 
METHODS 111 
Participants and study setting 112 
From Sept 21 to Dec 21, 2015 we conducted a prospective, single-arm, intervention study 113 
with healthy volunteers who resided in Lihir Island, New Ireland Province, Papua New 114 
Guinea (PNG). Eligible participants were male or female individuals aged 3 to 60 years with 115 
good general health by medical history, physical examination, baseline electrocardiographs 116 
and laboratory tests. Participants were excluded if they i) had a QT interval (adjusted using 117 
Fridericia’s correction; QTcF) greater than 450 ms or clinically significant abnormalities of 118 
rhythm at screening, ii) had a known history of additional risk factors for TdP, iii) had a 119 
family history of long QT syndrome or sudden cardiac death, iv) were using concomitant 120 
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medications known to prolong the QT/QTc interval, or v) had a history of relevant allergic 121 
reactions. All female participants in reproductive age were tested for pregnancy (urinary 122 
βHCG dipstick) and excluded if they were in the first trimester.  123 
The study protocol was approved by the PNG Institute of Medical Research – Institutional 124 
Review Board (number 15.01), the PNG Ministry of Health - Medical Research Advisory 125 
Committee (number 15.14), and the Ethics Committee of the Barcelona’s Hospital Clinic, in 126 
Spain (HCB/2014/0424). Written informed consent was obtained from all adult participants 127 
and, for children from parents or guardians.  128 
Study procedures 129 
We recruited a non-probabilistic convenience sample of healthy volunteers through group 130 
presentations by trained staff in 11 local communities, followed by one-to-one interviews. 131 
The volunteers were admitted at the hospital for a period of 72 hours, to facilitate drug 132 
administration under direct observation and fasting, and measurement of ECG traces. 133 
Arterakine® (Pharbaco Central Pharmaceutical, Vietnam) was given daily for 3 days (i.e. at 134 
time 0, 24 and 48 hours) following the dosing schedule of the PNG National Malaria 135 
Treatment Protocol, DHA/PQP 2.1/17.1 mg/kg (11). Patients were fasted for the three hours 136 
before and after each DHA/PQP dose. 137 
Detailed physical examination, routine clinical laboratory tests, pregnancy test for women of 138 
reproductive age, a rapid diagnostic test (RDT) for malaria, and a malaria blood slide were 139 
performed at baseline (time 0 hours) prior to treatment. Participants were assessed for adverse 140 
events (AEs) with a structured questionnaire and examination every 8 hours throughout day 3 141 
(i.e. at time 48, 56, 64 and 72 hours) of each course. Examination included measurement of 142 
blood pressure, pulse, respiratory rate, cardiac auscultation, respiratory auscultation and 143 
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abdominal palpation for all participants. Blood samples to analyse drug levels were collected 144 
on 52h (4h after third dose) of each administration course.  145 
Electrocardiography and electrocardiographic endpoints 146 
Twelve-lead ECG readings were conducted using an ELI 150 Cardiograph® at 25 mm/sec 147 
speed at pre-dose (at time 0 hours, in triplicate), immediately prior to administration of the 148 
third dose (at time 48 hours, single trace), and 4h after the third dose (at time 52 hours, in 149 
triplicate). For ECGs taken in triplicate, parameter measurements for the final analysis were 150 
based on the arithmetic mean of measurements from the 3 readings. Participants were 151 
discharged 24 hours after the last dose of treatment (at time 72 hours). In addition, ECGs 152 
were conducted at 7 days after the start of treatment and before (at time 0 hours) the 153 
following treatment course. The same procedure was repeated for the second and the third 154 
monthly treatment courses. Throughout the study period ECG readings were conducted at 12 155 
time-points over the 63-day follow-up period: day 0 pre-dose (0h course1), day 2 pre-dose (48h course1), 156 
day 2 post-dose (52h course1), day 7 (7 days course1), day 28 pre-dose (0h course2), day 30 pre-dose (48h 157 
course2), day 30 post-dose (52h course2), day 35 (7 days course2), day 56 pre-dose (0h course3), day 58 pre-dose 158 
(48h course3), day 58 post-dose (52h course3), and day 63 (7 days course3). 159 
The QT interval (i.e, distance from the Q wave to the end of the T wave) was corrected for 160 
heart rate using Fridericia’s correction formula (QTcF). This was defined as the measured QT 161 
interval divided by the cube root of the RR interval. The auto-calculated QTcF measurements 162 
were manually verified by the study clinician for safety purposes. All ECGs were 163 
electronically transferred to a cardiac core lab (Banook/Cardiabase in France) where 164 
independent and centralized interpretation of the tracings were repeated by a certified 165 
cardiologist blinded to the participant’s details. The following parameters were obtained: RR 166 
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(ms), HR (bpm), PR (ms), QRS (ms), QTcF (ms), and ΔHR (bpm), ΔPR (ms), ΔQRS (ms), 167 
ΔQTcF (ms) by comparison with baseline ECG (time 0 hours) for each course of treatment.  168 
A Data Safety Monitoring Board (DSMB) was established to which the site clinician (PM) 169 
was responsible for reporting any AE classified as either “Adverse Events of Special Interest” 170 
(AESI) or “Severe Adverse Events” (SAE) according to whether they met pre-specified 171 
criteria: We defined AESI as QTcF prolongation from baseline >60 ms; QTcF at any time 172 
>450 ms; T wave morphologic changes during therapy; bundle branch block or any new 173 
arrhythmia. We defined cardiologic SAEs as QTcF >500 ms (sensitivity is 94% and 174 
specificity 97% for prediction of malignant arrhythmia in overdose schedules), any malignant 175 
ventricular arrhythmia (e.g. TdP) or any episode of sudden death (12). We established a pre-176 
determined threshold for study cessation as the occurrence of three episodes meeting any of 177 
our criteria for a cardiologic SAE. 178 
Statistical analysis 179 
The primary endpoint of the study was ΔQTcF, calculated as the difference between QTcF 180 
measured at 0 h recording to 52h of each of the three courses. Secondary endpoints were i) 181 
occurrence of AESI and SAEs and ii) QTcF resolution. For analysis of the primary endpoint, 182 
we estimated the risk difference and two-sided 95% CIs in ΔQTcF between the ECG at 52h 183 
course 3 and the ECG at 52h course 1 using a paired T-test for comparisons. For analysis of the 184 
secondary endpoints, we estimated the risk difference and two-sided 95% CI for the 185 
difference in QTcF between the ECG at 0h course3 and the ECG at 0h course1, we also looked at 186 
the difference between the ECG at 7days course3 and ECG at 7days course1. We counted and 187 
summarized the number of AESIs and we used the McNemar test to compare the difference 188 
in occurrence of AESIs between the third and first courses of treatment. Data analysis was 189 
performed using Stata 15.1 software (Stata Corporation, College Station, TX, USA).  190 
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We calculated that 73 individuals would be required for the primary analysis to estimate a 5 191 
ms difference in mean QTcF prolongation between the first and third treatment course 192 
(assuming a prolongation in mean QTcF of 20 ms for the first month and 25 ms for the third 193 
month) with a confidence level of 95% and a power of 80%. Assuming that 10% of 194 
participants would be lost to follow up, the target recruitment was 82 individuals. 195 
 196 
RESULTS 197 
Of 110 individuals screened, 84 (76.3%) met the inclusion criteria and consented to 198 
participate in the study. Eighteen declined consent and 8 were ineligible (first trimester 199 
pregnancy, n=2; uncontrolled hypertension, n=2: asymptomatic arrhythmia, n=2; clinical 200 
heart failure, n=1; and congenital heart disease, n=1). Of the 84 participants who were 201 
initially enrolled, 69 (82.2%) completed all treatment courses and follow-up appointments 202 
(per-protocol population) and were included in subsequent analysis. 203 
The mean age of participants in the per-protocol population was 27.4 years (SD 12.6); 7 204 
(10%) were children (aged 3-15), and 34 (49%) were female. One female participant was 205 
pregnant (confirmed second trimester by dates and clinical examination).  At baseline the 206 
mean QTcF was 397.3 ms (SD 17.2). Sixty-five (94%) participants had a normal baseline-207 
ECG and 4 (6%) participants had minor abnormalities of no clinical relevance (i.e. 3 with 208 
non-pathological T-wave inversion and 1 with poor R-wave progression). Comparison of 209 
baseline demographic, clinical and electrocardiographic characteristics of participants that 210 
completed follow up and those that were lost to follow up were not-significantly different 211 
(Table 1). 212 
11 
 
The mean (SD) ΔQTcF (from 0 h to 52 h) was 19.6 ms (17.8) in course 1, 23.6 ms (15.3) in 213 
course 2 [difference 4.0 ms (95% CI 0.1 to 8.0); p =0.043], and 17.1 ms (17.1) in course 3 214 
[difference -2.4 (95%CI -6.9 to 2.1); p=0.285; Table 2 and Figure 1 and 2].  215 
In subgroup analyses (Supplementary Table S1), the mean (SD) ΔQTcF was higher in 216 
females [25.8 ms (20.5)] than in males [13.5 ms (12.2)] after course 1 (p=0.003). However, 217 
there was no significant difference in ΔQTcF between males and females after the second and 218 
third courses [22.7 ms (15.9) in males and 24.5 ms (14.9) in females, p=0.623 for the second 219 
course; and 14.3 ms (15.5) in males and 20.1 ms (18.4) in females, p=0.158 for the third 220 
course]. Mean QTcF segment and ΔQTcF did not differ significantly according to age group 221 
(data not shown).  222 
Figure 1 shows the evolution of QTcF at all time-points (days 0, 2, 7, 28, 30, 35, 56, 58, and 223 
63). Table 3 shows the resolution in ECG parameters at 7 days after the start of each 224 
DHA/PQP treatment course and prior (at 0 hours) of the following course. QTcF 0 h course3 225 
was shorter compared to QTcF 0 h course1 (-4.0 ms, p<0.001), which represents a full 226 
resolution of the QTcF prolongation 28 days after the start of treatment course 2. QTcF and 227 
ΔQTcF parameters on 7d course 2 and 7d course 3 showed no differences compared to 7d course 1 228 
(Supplementary Table S2).  229 
No participant had cardiac related SAEs during the study period. Table 4 shows the recording 230 
of cardiac AESIs occurring any time during the 63-day study observation period. ΔQTcF >60 231 
ms was observed in 3 (4.3%), 1 (1.4%, p=0.50), and 2 (2.9%, p=1.00) after the first, second 232 
and third course of treatment, respectively. None of the participants had QTcF readings of 233 
more than 500 ms. QTcF readings of ≥450 to <500 ms were noted in 6 (8.9%), 5 (7.2%, 234 
p=1.00), and 5 (7.2%, p=1.00) after the first, second and third course of treatment, 235 
respectively. Other reported cardiac AESIs included sinus bradycardia (<40 bpm) in 1 (1.4%) 236 
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participant in each treatment course, and 2 (2.9%) participants with changes in T-wave 237 
morphology after the second course of treatment. No AESIs were accompanied by clinical 238 
symptoms. Other previously defined AESIs (new bundle branch block and arrhythmia of new 239 
appearance) were not reported in any participant at any time during the study. 240 
Non-cardiac AEs occurred in 29 (14.0%) of 207 patient-visits. All reported AEs were mild 241 
and transient, with no participant requiring specialised treatment. The most commonly 242 
reported AE was abdominal pain (n=12, 5.8%), followed by headache (3.8%), cough (2.4%), 243 
and nausea (1.9%). All RDTs and microscopy smears collected at 0 h course2 and 0 h course3 were 244 
negative for malaria parasitaemia. 245 
Other ECG measurements (HR, ΔHR, PR, ΔPR, QRS and ΔQRS) along the 63 days of 246 
evolution are described in supplementary tables S3 and S4. 247 
 248 
DISCUSSION 249 
In this study three monthly repeated courses of DHA/PQP resulted in our primary study 250 
endpoint, change in mean post-final dose QTcF between the first and final courses,  of 17.7 251 
ms; a magnitude generally similar to those described after a single course and lying below the 252 
U.S Food and Drug Administration’s 20 ms threshold of high level of concern (13). Our 253 
findings that QTcF prolongation did not increase in a cumulative manner with repeat courses 254 
was supported by the observation that QTcF interval returned to normal prior to each 255 
subsequent course of treatment. Interestingly, the QTcF difference increased slightly (23.6 256 
ms) after the second but not the third course. This result is intriguing and will require 257 
correlation with drug concentrations once the results related to the drug’s pharmacokinetics 258 
of the current study become available. In addition, it is reassuring that no individual had any 259 
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QTcF > 500 ms and that the number of cases with an absolute increase >60 ms were limited 260 
to 6 individuals, evenly spread through each of the monthly courses. This therefore does not 261 
add to concerns raised by a recent large multicentric clinical trial about the possibility of 262 
increased incidence of this event after a repeated dose (7). Our results support previous 263 
findings that QT/QTc prolongation following DHA/PQP administration is consistently lower 264 
than that caused by other commonly used antimalarial drugs such as quinine (14, 15) or 265 
chloroquine (16). Previous studies assessing the cardiotoxicity of DHA/PQP have shown 266 
minimal QTc prolongation following a single 3-day course. For example, in Cambodia the 267 
mean (corrected by Bazett’s formula; QTcB) prolongation in 62 individuals was 11 ms 24 h 268 
after first dose (17) and the mean QTcF prolongation in 56 adults in Thailand it was 29 ms 52 269 
h after the start of treatment (18). In a cohort of 1002 malaria patients from a study conducted 270 
in four African countries, only 3 (0.3%) had QTcF >500ms after standard 3-dose treatment 271 
(one-month course) and less than 10% of participants had an increase in QTcF more than 60 272 
ms from baseline (19). A recent metanalysis of 11 studies involving repeated exposures of 273 
DHA/PQP for seasonal malaria chemoprevention or treatment of clinical malaria found no 274 
increased incidence of AEs with repeated dosing; however, only one of these (an unpublished 275 
study in 13 pregnant women) performed electrocardiographic assessments of QTc 276 
prolongation). The authors called for more studies incorporating electrocardiogram 277 
measurements (4). Recent MDA programmes using DHA/PQP in large populations have 278 
shown that this drug combination is safe to use due to the minimal occurrence of serious 279 
adverse events; however, electrocardiographic assessments were not performed to monitor 280 
cardiac side effects (20-22). 281 
Several secondary observations are worth noting, including gender differences in the 282 
measurements of QT related parameters. The study showed an increase in QTcF among 283 
females at all time points that is consistent with previous studies (23, 24). Regarding AEs, 284 
14 
 
less than one fifth of patients reported mild abdominal pain, headache, cough or nausea. All 285 
appeared to be self-limiting and none required specific treatment or intervention. Although 286 
this trial was not designed to evaluate the efficacy of DHA/PQP, all participants remained 287 
parasite negative for the duration of the study. This lack of breakthrough infections, in an 288 
area where malaria transmission is high (5, 6, 25) and endogenous Plasmodium vivax relapses 289 
are common, reassuringly suggested that post-treatment prophylaxis was satisfactory. 290 
This study, however, does present certain limitations. The first one includes the lack of a 291 
control group, that may hinder some of the interpretation of our results. Another limitation 292 
was the relatively high attrition rate that saw 18% of enrolled participants fail to complete the 293 
scheduled follow-up appointments and were therefore excluded from our per-protocol 294 
analysis. If those lost to follow-up had been prone to greater QTc prolongation, this could 295 
have been a source of bias. However, there were no statistically significant differences in 296 
baseline characteristics between participants who were lost to follow-up compared with those 297 
who completed follow-up. We also acknowledge an issue of generalizability of our findings 298 
regarding the way we managed food co-administration in this study. Administration of 299 
DHA/PQP with food, particularly fat, increases the bioavailability leading to increased drug 300 
concentrations and greater degree of QT prolongation (8). We carefully controlled this by 301 
advising all participants to avoid food intake for the 3 hours before and after drug 302 
administration. However, whilst feasible in the context of a tightly controlled research study, 303 
this level of compliance may be difficult to achieve in a real MDA campaign delivered at 304 
very large scale. Hence, it is possible that individuals not following this dietary advice could 305 
be prone to greater drug absorption, higher cumulative doses and greater QTc prolongation 306 
than seen in our study.  307 
Our primary endpoint examined changes in mean QTcF values, consistent with US FDA and 308 
other regulatory bodies. However, in terms of population risk, the way in which values are 309 
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distributed across populations is perhaps more important than the measures of centrality 310 
reported here. It is those individuals who lie on the upper edge of the population distribution 311 
who are most important. For example, if an MDA intervention is deployed in 100,000 people, 312 
presuming that QTc distribution has a normal population distribution, 2,500 will have QTc 313 
prolongations that are 2SD above the population mean. These would be the individuals of 314 
greatest risk of a serious cardiac event. Our clinical study, like all others performed to date, 315 
did not have anywhere near the sample size required to define the population distribution 316 
accurately enough to define risk in this group. In practice, the only way this will ever be 317 
further clarified is by robust pharmacovigilance employed during large-scale MDA 318 
implementation programs. 319 
In this study, all patient QTc measurements after three courses of DHA/PQP treatment were 320 
within approved safety margins outlined by US drug regulatory institutions. The data do not 321 
suggest that the known risk of QT prolongation increases cumulatively with repeated monthly 322 
courses out to the 3rd course. However, the observation of slightly increased QT prolongation 323 
after two courses of treatment requires further investigation. At this stage, data from this 324 
study, together with the lack of reported adverse cardiac events in repeated-course MDA 325 
intervention programs elsewhere (5, 25), suggest that DHA/PQP can be used safely as MDA 326 
delivered using conventional dosing in up to 3 monthly rounds as a tool for malaria 327 
elimination. Cautions need to be articulated in relation to the antimalarial major drawbacks. 328 
First, multidrug resistance could reduce the impact, therefore monitoring of the drug’s 329 
efficacy will be required (26). Second, the three daily doses required for each round of MDA 330 
result in a major logistic burden and stretch the tolerance of the target population. 331 
Nevertheless, the absence of a single dose antimalarial with safety data for repeated dosing, 332 
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FIGURE LEGENDS: 463 
Figure 1. Electrocardiographic QTcF measurements over the study period  464 
Legend: Results are median and Interquartile Ranges (IQR) of all QTcF (QT corrected by 465 
Fridericia’s correction) measurements over the 63 days of study. Arrows are the DHA/PQP 466 
doses. Day 0 corresponds to 0h value of each month, day 2 values correspond to 48h (pre-467 
dose) and 52h (4h post-dose) measurements and Day 7 value is the value of the Day 7 468 
measurement of each month.  469 
 470 
Figure 2. Changes in the QTcF measurements (ΔQTcF) over the study period 471 
Legend: Results are mean and standard deviation (SD) of the ΔQTcF (difference in QT 472 
corrected by Fridericia’s correction between baseline and each point of measurement) over 473 
the 63 days of study.  0hcourse1 corresponds to day 0 pre-dose, 52hcourse1 corresponds to day 2 474 
post-dose, day7course1 corresponds to day 7 post-dose, 0hcourse2 corresponds to day 28 pre-dose, 475 
52h course2 corresponds to day 30 post-dose, day7course2 corresponds to day 35, 0hcourse3 476 
corresponds to day 56 pre-dose, 52h course3 corresponds to day 58 post-dose and day7course3 477 
corresponds to day 63.  478 
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Table 1. Comparison of baseline characteristics of participants that completed follow up 479 
and participants that were lost to follow up.  480 
Variable Status p-value 
Finish study Lost to follow up Total 
Demographic variables 
Sex Male 35 (51%) 11 (73%) 46 (55%) 0.111 
Female 34 (49%) 4 (27%) 38 (84%) 
Age (years)  27.4 (12.6) 29.6 (12.8) 27.8 (12.6) 0.546 
<15 years old 7 (10%) 1 (7%) 8 (10%) 1.000 
≥15 years 62 (90%) 14 (93%) 76 (90%) 
Clinical variables 
Hypertension No 68 (99%) 15 (100%) 83 (99%) 1.000 
Yes 1 (1%) 0 (1%) 1 (1%) 
Diabetes No 69 (100%) 15 (100%) 84 (100%)       _ 
Yes 0 (0%) 0 (0%) 0 (0%) 
Chronic 
treatment 
No 68 (99%) 14 (93%) 82 (98%) 0.327 
Yes, no related with 
risk of QT 
enlargement 
1 (1%) 1 (7%) 2 (2%) 
Temperature (ºC) 35.5 (0.9) 35.2 (1.1) 35.4 (0.9) 0.238 
Cardiac 
auscultation 
No alterations 64 (93%) 15 (100%) 79 (94%) 0.580 
Presence of murmur 5 (7%) 0 (0%) 5 (6%) 
Splenomegaly No 64 (93%) 15 (100%) 79 (94%) 0.580 




Negative 63 (91%) 15 (100%) 78 (93%) 1.000 
Positive P.falciparum 4 (6%) 0 (0%) 4 (5%) 
Positive P.vivax 1 (1%) 0 (0%) 1 (1%) 
Positive P.malariae 1 (1%) 0 (0%) 1 (1%) 
Glucose (mmol/L) 4.8 (3.7) 5.4 (1.4) 4.9 (3.4) 0.564 
Creatinine (µmol/L) 70.7 (26.5) 79.6 (26.5) 70.7 (26.5) 0.370 
Sodium (mmol/L) 139.9 (3.8) 141.7 (1.4) 140.2 (3.5) 0.083 
24 
 
Potassium (mmol/L) 4.0 (0.3) 4.3 (0.3) 4.1 (0.3) 0.018 
Haemoglobin (g/dL) 12.5 (2.1) 13.1 (2.0) 12.6 (2.1) 0.309 
ECG parameters 
Heart rate (bpm) 68.4 (12.4) 73.8 (11.6) 69.4 (12.3) 0.127 
PR segment (ms)  166.9 (18.7) 165.1 (22.0) 166.6 (19.2) 0.749 
QRS segment (ms) 90.9 (9.5) 92.7 (9.2) 91.2 (9.4) 0.525 
QTcF segment (ms) 397.3 (17.2) 391.6 (18.8) 396.3 (17.5) 0.255 




4 (6%) 3 (20%) 7 (8%) 
Legend: For quantitative variables results are described in mean ± Standard Deviation (SD); 481 
for qualitative variables results are described in numbers and percentage (%). P-value 482 
corresponds to the results of the paired T-test comparing both groups. Abbreviations: bpm= 483 
beats per minute; ms= milliseconds. Statistically significant results are reflected in bold. 484 
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Table 2. Electrocardiographic measurements of QTcF and ΔQTcF at 52 hours post dose during the second and third monthly course 485 
with dihydroartemisinin-piperaquine compared with the first month. 486 
Legend: 52h readings were conducted 4h after administration of the third dose. The parameter measurements are the arithmetic mean of 487 
measurements from the triplicate reading. Results of measurements, p-values and 95%CI for the paired t-test for comparison with measurement 488 
of 52h course1. Measurements are described in mean ± Standard Deviation (SD). Abbreviations: ms= milliseconds. Statistically significant results 489 







0h course1 52h course1 
  
52h course2 p-value 
Risk difference 
(95%CI) 
52h course3 p-value 
Risk difference 
(95%CI) 
QTcF (ms) 397.3±17.2 416.8±23.4 421.0±19.8 0.040 4.1 (0.2 to 8.1) 414.3±23.6 0.270 -2.5 (-7.1 to 2.0) 
ΔQTcF (ms) - 19.6±17.8 23.6±15.3 0.043 4.0 (0.1 to 8.0) 17.1±17.1 0.285 -2.4 (-6.9 to 2.1) 
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Table 3. Electrocardiographic measurements of QTcF and ΔQTcF at 7 days after the start of each course of DHA/PQP and before the 494 
start (at 0 hours) of the following monthly course compared with 0h measurements on day0 first course. 495 
Legend: Results of measurements and p-values for the paired t-test for comparison with baseline 0h course1 measurements. Measurements are 496 





7d course1 0h course2 7d course2 0h course3 7d course3 
measurement p-value measurement p-value measurement p-value measurement p-value measurement p-value 
QTcF (ms) 397.3±17.2 405.7±20.9 <0.001 393.9±18.1 0.043 407.7± 22.7 <0.001 389.9±18.9 <0.001 407.7±22.4  <0.001 
ΔQTcF (ms) - 8.0±15.7 - -3.7±13.3 - 10.1±16.1 - -7.4±14.8 -  11.0±16.9 -  
27 
 
Table 4. Adverse Events of Special Interest recorded on 52h of each treatment course. 499 
 
            AESI description 











with course 1 
QTcF prolongation >60 ms  3 (4.3%) 1 (1.4%) 0.50 2 (2.9%) 1.00 
QTcF ≥450 ms <500 ms 6 (8.7%) 5 (7.2%) 1.00 5 (7.2%) 1.00 
Sinus bradycardia <40 bpm 1 (1.4%) 1 (1.4%) 1.00 1 (1.4%) 1.00 
T wave morphologic changes 0 (0.0%) 2 (2.9%) 0.50 0 (0.0%) - 
 500 
Legend: Results are described in number of cases (N) and percentage (%) in the per-protocol study population. P-values results are shown for the 501 
exact McNemar significance probability test. AESI: Adverse Event of Special Interest. Other AESIs: none (0) cases of new bundle branch block 502 
and none (0) of arrhythmia of new appearance were described.   503 
 504 
 505 




